Abstract: A process for fabricating an integrated electronic circuit comprises the formation of at least one air gap between interconnect elements above only a defined portion of a surface of a substrate, within an interconnect layer. The interconnect layer comprises a sacrificial material and extends beneath an intermediate layer of permeable material. The air gap is formed by removal, through the intermediate layer, of at least part of the sacrificial material by bringing the permeable material into contact with an agent for removing the sacrificial material, to which agent the permeable material is resistant.

Abstract: A sealed type container accommodating a semiconductor substrate is positioned to a load port of a semiconductor manufacturing apparatus. The semiconductor substrate is taken out of the container. An ionizer is used for static-charge-eliminating the semiconductor substrates before and after process treatment in a transport area between the load port and a treatment section. The static-charge-eliminated semiconductor substrate is accommodated in the container positioned to the load port. Thus, it is possible to decrease foreign materials adhering to the semiconductor substrate and errors in handling the semiconductor substrate.

Abstract: An industrial fabric having improved sheet restraint and wear resistance along with acceptable permeability. The improvement is effected by coating only the high spots of the fabric with silicone material. The coating methods used in this invention may include kiss roll coating, gravure roll coating, rotogravure printing, rotary screen coating, screen-printing and/or flexography. The improvement is also applicable to corrugator fabrics.

Abstract: The invention discloses an SiO2—TiO2 glass, which is preferably made by flame-hydrolysis and which distinguishes itself by increased resistance to radiation, especially in connection with EUV lithography. By purposefully reducing the hydrogen content, clearly improved resistance to radiation and reduced shrinking is achieved.

Abstract: A ceramic fuse housing is provided for surface mount circuit protectors, wherein a selectively destructible fuse is at least partially retained within the fuse housing. The fuse housing being formed of between 80% to 90% alumina and 20% to 10% zirconia, wherein 5% to 25% of the zirconia is in a tetragonal phase.

Abstract: A dielectric ceramic, and capacitor with the ceramic, wherein the ceramic has: about 94–99.9 wt % a first component defined by Formula 1; [(Ca1-xSrx)O]m(Zr1-yTiy)O2Formula 1 wherein: x is no more than about 0.6; and y is no more than about 0.1; and m is at least about 0.85 to no more than about 1.15; and about 0.1–5 wt % a secondary component defined by Formula 2; aSiO2-b[?B2O3-(1??)Li2O]-cAOFormula 2 wherein: a, b and c are selected to lie within the region defined by points A(a=15, b=0, c=85), B(a=70, b=0, c=30), C(a=0, b=70, c=30) and D(a=0, b=15, c=85) of a ternary diagram wherein a is mole percent SiO2; b is mole percent ?B2O3-(1??)Li2O; and c is mole percent AO and a+b+c=100 including the lines BC, CD and AD but excluding the line AB; ? is 0 to 1; A is selected from Mg, Ca, Sr, Ba or a combination thereof; and 0–2 wt % MnO2.

Abstract: A catalytic composition, including a cationic metal-pair complex, is disclosed, along with a method for its preparation. A method for the polymerization of ethylenically unsaturated monomers using the catalytic composition, and the addition polymers produced thereby are also disclosed.

Abstract: Bimetallic catalysts, and methods of producing a bimetallic catalyst comprising a modified Ziegler-Natta catalyst and a metallocene are provided, in one embodiment the method including combining: (a) a Ziegler-Natta catalyst comprising a Group 4, 5 or 6 metal halide and/or oxide, optionally including a magnesium compound, with (b) a modifier compound (“modifier”), wherein the modifier compound is a Group 13 alkyl compound, to form a modified Ziegler-Natta catalyst. Also provided is a method of olefin polymerization using the bimetallic catalyst of the invention. The modified Ziegler-Natta catalyst is preferably non-activated, that is, it is unreactive towards olefin polymerization alone. In one embodiment, the molar ratio of the Group 13 metal (of the modifier) to the Group 4, 5 or 6 metal halide and/or oxide is less than 10:1 in one embodiment.

Abstract: A catalyst component for ethylene polymerization, including an inorganic oxide support, and at least one alkyl metal compound, at least one halide, at least one dihydrocarbyl magnesium compound, at least one difunctional compound that reacts with the dihydrocarbyl magnesium compound and at least one titanium compound, wherein the difunctional compound is a mono-, di- or multi-halogenated alcohol or phenol having from 2 to 20 carbon atoms; or a mono-, di- or multi-halogenated acyl halide having from 2 to 20 carbon atoms. Also, a process for preparing the catalyst component and use thereof.

Abstract: In a process for preparing alcohols by catalytic hydrogenation of carbonyl compounds over a catalyst comprising rhenium on activated carbon, the catalyst used comprises rhenium (calculated as metal) in a weight ratio to the activated carbon of from 0.0001 to 0.5, platinum (calculated as metal) in a weight ratio to the activated carbon of from 0.0001 to 0.5 and, if appropriate, at least one further metal selected from among Zn, Cu, Ag, Au, Ni, Fe, Ru, Mn, Cr, Mo, W and V in a weight ratio to the activated carbon of from 0 to 0.25, and the activated carbon has been nonoxidatively pretreated. It is also possible to prepare ethers and lactones if the hydrogen pressure is not more than 25 bar. In this case, the activated carbon in the catalyst may also have been nonoxidatively pretreated.

Abstract: The invention relates to highly active spherical metal support catalysts with a metal content of 10 to 70% by mass, and a process for their production with the use of a mixture of polysaccharides and at least one metal compound which is dropped into a metal salt solution.

Abstract: An integrated system for individually labeling a recording medium at the time that digital information is recorded thereon, by recording write data with a digital recorder on the read/write surface of the CD/DVD and recording image data by inducing visible color change with a laser in laser sensitive materials on the opposite surface of the CD/DVD.

Abstract: The present invention provides a receptor element for use in thermal transfer imaging. The receptor element includes a coating having a polymeric binder and a biguanide bleaching agent. The biguanide bleaching agent is capable of bleaching an infrared-absorbing dye when the biguanide bleaching agent and the infrared-absorbing dye are in contact. A particularly suitable biguanide bleaching agent is 1-(o-tolyl)biguanide. The invention also provides compositions and methods for manufacturing a receptor element. Also provided by the invention is an imaging system for thermal transfer imaging. The imaging system includes a color-bearing element and a bleaching element, wherein the bleaching element includes a coating having a polymeric binder and a biguanide bleaching agent. The invention further provides methods useful in the production of integral proofs.

Abstract: There are provided an intermetallic compound superconductor that is high in superconducting transition temperature, and an alloy superconductor that is high in superconducting transition temperature and excels in malleability and ductility, as well as a method of making such a superconductor with good reproducibility and at a low cost of manufacture. This entirely new intermetallic compound superconductor is made of magnesium (Mg) and boron (B) and has a chemical composition expressed by formula: Mg1B2, has a hexagonal AlB2 type crystallographic structure and has a superconducting transition temperature (Tc) of 39 K. An alloy containing this intermetallic compound excels in malleability and ductility and constitutes the alloy superconductor having a superconducting transition temperature (Tc) of 39 K. In the method of manufacture, a Mg containing feedstock powder and a B containing feedstock powder are mixed together to form a mixture thereof which is, e.g., hot pressed to produce a semiconductor product.

Abstract: The present invention is directed to compounds which possess unique organoleptic propertied of the general formula wherein R is a hydrogen or selected from the group consisting of C1–C7 moieties and the use of these materials as a fragrance chemical to enhance fragrance in perfumes, toilet waters, colognes, personal products and the like.

Abstract: A person's skin is protected from percutaneous absorption of lipophilic or semi-polar contaminant chemicals by applying to the skin, before the skin is wetted with water, a plural-constituent solvent system having an average molecular weight greater than or equal to 350 and including at least one solvent in which the contaminant chemicals are soluble. The solvent system may be applied to the skin before exposure to serve as a barrier, or may be applied to the skin or other surface after exposure to serve as a cleanser. The solvent system may include one or more emulsifiers and/or reactive chemical deactivation agents, and/or organic pH modifiers, and/or UV blockers, and/or insect repellents. Oil-based and glycol-based solvent systems are disclosed, each having at least two solvents which may have different solubility ranges. The solvent system includes no water, emollients or detergents and all constituents are skin-safe.

Abstract: The present invention relates to a composition for cleaning a photoresist and is to provide a cleaning composition wherein the residue of the photoresist does not remain on the boundary surface between the cleaned area and the not-cleaned area after a negative photoresist containing pigment is cleaned, soft-baked, exposed and developed. The present invention provides a composition for cleaning a positive or negative photoresist which comprises (a) from 0.1 to 20 wt. % of and alkyl oxide polymer with a molecular weight of from 50 to 2000 and (b) from 80 to 99.9 wt. % of an organic solvent comprising: (b?1) from 1 to 20 parts by weight of dipropylene glycol methyl ether (DPGME), from 10 to 50 parts by weight of N-methyl pyrolidone (NMP) and from 50 to 90 parts by weight of methyl isobutyl ketone (MIBK), or (b?2) from 10 to 90 parts by weight of dimethyl formaldehyde (DMF) or dimethylacetamide (DMAc) and from 10 to 50 parts by weight of n-butyl acetate.

Abstract: The present invention relates to lipolytic enzyme variants with improved thermostability are obtained by substituting certain specified amino acid residues in a fungal lipolytic enzyme. The thermostable lipolytic enzyme variants are useful, e.g., for controlling pitch troubles in a process for the production of mechanical pulp or a paper-making process using mechanical pulp.

Abstract: Non-aqueous based fragrance compositions containing a siloxane material are disclosed. The fragrance compositions are suitable for many applications including cosmetics, laundry care and personal care items. The fragrance compositions can also be used in air fresheners, particularly those air fresheners that contain heating elements.

Abstract: The present invention concerns processes for the production of dry, partially amorphous products containing biologically active and in particular therapeutically active material which are macroscopically homogeneous substance mixtures, the substance mixtures being selected from at least one substance of each of the groups (i) carbohydrate or zwitterion with a polar residue and derivatives thereof, and (ii) zwitterion with an apolar residue and derivatives thereof, wherein a solution is prepared of the biologically or therapeutically active material and of substances (i) and (ii) and the solution is dried at a product temperature above the freezing point of the solution. In addition the invention concerns new substance mixtures which are obtained by the said process as well as the use thereof in diagnostic or therapeutic methods.

Abstract: A modified factor VIIa is provided. The modified factor has increased amidolytic activity in the absence of T.F. and a higher affinity for T.F. when compared to the native factor VIIa but does not have substantially altered proteolytic activity when bound to T.F. Nucleic acid molecules that encode the factor, expression vectors that contain the nucleic acid molecules, cells that contain the nucleic acid molecules, and cells transformed with the expression vector are also provided. In a preferred embodiment, the modified factor is a human factor VIIa.

Abstract: The present invention relates to a method for regulating neuron development/maintenance and/or regeneration in a nervous system of a mammal and to pharmaceutical compositions comprising leukaemia inhibitory factor useful for same.

Abstract: The present invention relates to a TGF-?1 binding protein called r150. This protein has a GPI-anchor contained in r150 itself and not on a tightly associated protein and that it binds TGF-?1 with an affinity comparable to those of the signaling receptors. Furthermore, the released (soluble) form of this protein binds TGF-?1 independent of the types I and II receptors. Also, the soluble form inhibits the binding of TGF-? to its receptor. In addition, evidence that r150 is released from the cell surface by an endogenous phospholipase C is provided. Also, the creation of a mutant human keratinocyte cell line with a defect in GPI synthesis which displays reduced expression of r150 is described. Our results using these mutant keratinocytes suggest that the membrane anchored form of r150 is a negative modulator of TGF-beta responses.

Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

Abstract: Macrocyclic isoquinoline peptides are disclosed having the general formula: A compound of formula I: wherein R1 to R9, Q and W are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonist peptides may also be developed as therapeutics.

Abstract: The present invention relates to a combination of peptides that may be used for treatment of cancer. The peptide combination competes for the binding of specific neuropeptides at the plasma membrane and thereby alters the levels of key intracellular molecules implicated in cell proliferation, resulting in a broad spectrum of anticancer activity. The invention also relates to pharmaceutical compositions containing a combination of such peptide analogs.

Abstract: The disclosure provides a novel class of cationic cathelin-like peptides and polypeptides that have antimicrobial activity. These peptides are useful for inhibiting microbial infection or growth.

Abstract: The invention relates to a lyophilized HGF preparation prepared by lyophilizing an aqueous solution containing HGF, and a lyophilized HGF preparation containing a stabilizer, sodium chloride, a buffer, and/or a surface active agent. According to the invention, HGF can be stabilized, and it can be stored for a long period.

Abstract: Novel surfactant protein C esters suitable for preparing pharmaceutical compositions for the treatment of infant respiratory distress syndrome and adult respiratory distress syndrome are described.

Abstract: The present invention provides Orphanin FQ receptor nucleic acids and polypeptides and uses thereof. In particular, the present invention provides nucleic acid sequences of differentially expressed splice variants of the Orphanin FQ receptor. The present invention also provides methods of using the Orphanin FQ receptor nucleic acid sequences and ligands for the identification of pharmaceutical agents, the generation of animal models of Orphanin FQ receptor-mediated disease states, and for formulating biological activities. The present invention further provides improved methods of screening potential therapeutics useful in the treatment of a variety of disease states mediated by Orphanin FQ signaling, as well as therapeutics identified using the screening methods.

Abstract: The present invention provides methods and kits for mitigating radiation induced tissue damage, improving the effectiveness of radiation therapy, to support bone marrow transplantation, and promoting megakaryocyte production and mobilization and platelet production, each method comprising the administration of an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists.

Abstract: A peptide of the formula (Xaa)n1-Xaa1-His-Thr-Asp-(Xaa)n2, wherein Xaa is any amino acid; Xaa1 is a hydrophobic amino acid, preferably Gly or Val; n1 is 0–10; and n2 is 0–10; and use thereof in regulating in vivo blood glucose levels in a human or other mammal, particularly in the treatment of Type 2 diabetes in a human. Preferably, the peptide is a tetrapeptide selected from Gly-His-Thr-Asp and Val-His-Thr-Asp. These hypoglycaemic peptides are isolated from human urine and they also have been chemically synthesized.

Abstract: Tuberculosis in an animal is treated by administration of a therapeutically effective amount of an immunomodulator of formula A. In formula (A), n is 1 or 2, R is hydrogen, acyl, alkyl or a peptide fragment, and X is an aromatic or heterocyclic amino acid or a derivative.

Abstract: Disclosed are synthetic oligonucleotides having a nucleotide sequences specifically complementary to nucleotides 324 to 345 of a conserved gag region of the HIV-1 genome, the oligonucleotide consisting of 21 nucleotides which are linked via phosphorothioate internucleotide linkages. Also disclosed are methods for inhibiting and treating HIV-1 and HIV-2 infection.

Abstract: The present invention relates, in general, to Syk kinase and, in particular, to a method of inhibiting Syk kinase expression using small interfering RNA (siRNA).

Abstract: Compositions and methods are provided for prevention and clinical treatment of various forms of graft-versus-host disease (GVHD) by using inhibitors of adenosine deaminase (ADA). In particular, various formulations and dosing regimens of ADA inhibitors such as pentostatin are provided for the treatment of all forms of GVHD, especially steroid-refractory acute and chronic GVHD.

Abstract: Pyrimidine nucleotide precursors including acyl derivatives of cytidine, uridine, and orotate, and uridine phosphorylase inhibitors, and their use in enhancing resistance to sepsis or systemic inflammation are disclosed.

Abstract: Disclosed are compounds having non-steroidal anti-inflammatory drugs (NSAIDS) covalently linked to a phospholipid moiety via a bridging group. Also disclosed are a process for the synthesis of the compounds, pharmaceutical compositions comprising the compounds and the use thereof for the treatment of diseases and disorders related to inflammatory conditions, such as the treatment of ischemia.

Abstract: The invention relates to compounds of the following formula (I). In these compounds, R1, R2, R3 and R4 are each independently a substituted or unsubstituted cyclitol with a ring comprising six carbon atoms, or hydrogen, substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, alkyloxycarbonyl, or alkylaminocarbonyl. At least two of R1, R2, R3 and R4 comprise the substituted or unsubstituted cyclitol. The linker can be any one of the following: —(CH2)w—, —(CH2)x—C6H4—(CH2)x—, —(CH2)y—NR5—(CH2)y—, and —(CH2)z—HCR6—(CH2)z—; wherein: w, x, y and z are independently an integer having a value of 0–10; R5 is a substituted or unsubstituted cyclitol with a ring comprising six carbon atoms; and, R6 is —OH, —OSO3Na, —OSO3Na substituted with alkyl, cycloalkyl or aryl, or substituted or unsubstituted alkyl, cycloalkyl or aryl. The compounds can also include substituted or unsubstituted cyclitol carbamides with the linker bond at the carbamide nitrogen.

Abstract: Novel phosphoramidate derivatives of hydroxy functional or amino functional compounds, including amino acids, peptides, peptidomimetics and nucleotide analogs, are described. The compounds enable enhanced intracellular delivery of drugs as their corresponding phosphate esters or amides. Described phosphoramidate compounds exhibit antiproliferative activity. Pharmaceutical formulations are provided for treatment of cancers.

Abstract: This invention relates to the use of temozolomide esters (4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxylate esters) Formula 1 as potent anticancer pro-drugs for treatment of cancers by topical and transdermal applications, and to a novel process for synthesis of temozolomide esters by a direct esterification of temozolomide acid (3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxylic acid) with a halogeno-aliphatic compound in presence of a base, or with an alcohol in presence of a dehydrate agent

Abstract: The invention encompasses a series cyclic bicyclic heterocyclic compounds of Formula I which are inhibitors of HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS.

Abstract: The present invention relates to novel benzazepine derivatives of the following formula: wherein R1, R2, R3, R4 and R5, X, X?, Y and Y? are as defined in the description and claims, processes for their preparation, pharmaceutical compositions containing said derivatives and their use for the preparation of medicaments useful for the prevention and treatment of diseases in which selective inhibition of monoamine oxidase B activity plays a role or is implicated.

Abstract: Compounds of the formula (I), wherein the symbol aa means a residue of an ?-amino acid. The invention is also directed to a method for the preparation of the compounds of formula (I), as well as their use as prolyl oligopeptide inhibitors, for example for the treatment of Alzheimer's disease.

Abstract: Compounds of formula (I), wherein G1 is CH or N; G2 is CH or N; R1 is a variety of optional substituents; L1 is (1-4C)alkylene; T1 is CH or N; R2 and R3 are independently hydrogen or (1-4C)alkyl or are joined to form a ring; X1 and X2 represent various linking groups; Ar is phenylene or certain heteroaryl rings and Q represents a variety of aromatic or heterocyclic rings systems, and pharmaceutically acceptable salts thereof are described as useful antithrombotic and anticoagulant agents, and are selective Factor Xa inhibitors. Processes for their preparation and pharmaceutical compositions containing them are also described.

Abstract: The present invention relates to synthesis of pyrrolo[2,1-c][1,4]benzodiazepine-anthraquinone hybrids (V) wherein n=3,4; R=H, OH and to their use as antitumour agents.

Abstract: Disclosed are cannabimimetic aminoalkylindole compounds and methos for their manufacture. The disclosed compounds are surprisingly potent and selective cannabinoinds. Also disclosed are methods of using the disclosed compounds, including use of the disclosed compounds to stimulate a cannabinoid receptor, to provide a physiological effect in an animal or individual and to treat a condition in an animal or individual.

Abstract: The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterised by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.

Abstract: The present invention provides a pharmaceutical composition which is useful as a phosphatidylinositol 3 kinase (PI3K) inhibitor and an antitumor agent, and it provides a novel bicyclic or tricyclic fused heteroaryl derivative or a salt thereof which possesses an excellent PI3K inhibiting activity and cancer cell growth inhibiting activity.